HIV: ABX464 A POTENTIAL CORNERSTONE OF A FUNCTIONAL CURE FOR HIV PATIENTS

ABX464 ABIVAX's lead drug candidate which prevents the export of viral RNA (Ribonucleic acid) in infected cells has the potential to transform the treatment of patients with HIV (Human Immune Deficiency Virus) and become a cornerstone of a functional cure, so says Professor Hartmut Ehrlich, CEO of ABIVAX, a Paris based company.
ABX464 prevents viral RNA being exported from the nucleus of a cell to the cytoplasm where protein synthesis takes place, mediated by a viral protein called REV.
The molecule ABX464 is the first to inhibit REV and as such has the potential to target both infected and non infected and cells unlike traditional anti-retrovirals which only prevent the infection of new cells, so says Professor Ehrlich.
He also did say that ABIVAX has received a lot of interest from big pharmaceutical companies about ABX464 and they are planning to partner with other companies at least for North America and Europe in Phase 111 trials and commercialization.